Risk Factors for Lenvatinib-Induced High-Grade Hypothyroidism in Patients with Hepatocellular Carcinoma: A Retrospective Study
Pharmacology · 2023
DOI: 10.1159/000531881 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology, 2023. Verfasst von Shusuke Uekusa und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, Chiba, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Hypothyroidism. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Introduction
Lenvatinib mesylate (LEN) is an orally administered tyrosine kinase inhibitor used for the treatment of various cancers, including hepatocellular carcinoma (HCC). HCC treatment with LEN is associated with a very high incidence of adverse events, especially hypothyroidism. This study investigated the incidence of hypothyroidism due to LEN and the relationships between hypothyroidism incidence and patient demographics by analyzing clinical laboratory data from HCC patients treated with LEN.
Methods
This was a single-center, retrospective study of HCC patients who received LEN between April 19, 2018, and September 30, 2020. The observation period was from 1 week before the start of LEN administration to 1 month after the end of administration.
Results
In total, 61 patients with HCC were enrolled. High-grade hypothyroidism (CTCAE Grade 2–3) was found in 36.1% (22/61 patients). In high-grade hypothyroidism, eosinophil (EOSINO) count was significantly low (p = 0.029). The cutoff value of EOSINO count was estimated to be approximately 150/µL. The adjusted odds ratios of high-grade hypothyroidism for current smoking and EOSINO count <150/µL were 0.237 (95% confidence interval: 0.063–0.893) and 4.219 (95% confidence interval: 1.119–15.92), respectively.
Conclusion
The results showed that noncurrent smoking and EOSINO count <150/µL are risk factors for LEN-induced high-grade hypothyroidism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, Chiba, Japan.
- Toho University Omori Medical Center, Tokyo, Japan.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan.
- Laboratory of Medical Biochemistry, Faculty of Pharmaceutical Sciences, Toho University, Chiba, Japan.
Zitieren
APA
Uekusa, S., Nemoto, M., Hanai, Y., Nakashin, M., Miyagawa, A., Yanagino, S., Arita, Y., Matsumoto, T., Nishizawa, K., Nagai, H., Higai, K., & Matsuo, K. (2023). Risk Factors for Lenvatinib-Induced High-Grade Hypothyroidism in Patients with Hepatocellular Carcinoma: A Retrospective Study. Pharmacology. https://doi.org/10.1159/000531881
Vancouver
Uekusa S, Nemoto M, Hanai Y, Nakashin M, Miyagawa A, Yanagino S, et al. Risk Factors for Lenvatinib-Induced High-Grade Hypothyroidism in Patients with Hepatocellular Carcinoma: A Retrospective Study. Pharmacology. 2023. doi:10.1159/000531881
BibTeX
@article{Uekusa2023,
author = {Uekusa, Shusuke and Nemoto, Maho and Hanai, Yuki and Nakashin, Misaki and Miyagawa, Arisu and Yanagino, Sachiko and Arita, Yoshiki and Matsumoto, Takahiro and Nishizawa, Kenji and Nagai, Hidenari and Higai, Koji and Matsuo, Kazuhiro},
title = {Risk Factors for Lenvatinib-Induced High-Grade Hypothyroidism in Patients with Hepatocellular Carcinoma: A Retrospective Study},
journal = {Pharmacology},
year = {2023},
doi = {10.1159/000531881}
}
EUVIMED